Key result
Selective risk-based screening for asymptomatic CAD in T2D may outperform universal testing.
Why the study?
Coronary artery disease often progresses silently in type 2 diabetes, and the clinical value of routine screening in asymptomatic individuals remains controversial.
Does selective screening for coronary artery disease improve risk stratification and outcomes in asymptomatic patients with type 2 diabetes?
Does selective screening for coronary artery disease improve risk stratification and outcomes in asymptomatic patients with type 2 diabetes?
A proactive, risk-based screening strategy using advanced imaging and biomarkers may improve the early identification and management of subclinical coronary artery disease in asymptomatic patients with type 2 diabetes.
May favor selective CAD screening in asymptomatic T2D; leaves open validation in randomized outcome trials.
Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type 2 diabetes. This population faces an increased risk of coronary artery disease due to accelerated atherosclerosis, endothelial dysfunction and chronic inflammation. A substantial proportion of cases remain clinically silent, with coronary artery disease often undetected until the occurrence of acute events. This silent progression poses a significant challenge for timely diagnosis and prevention. This review explores the prevalence, mechanisms, and prognosis of asymptomatic coronary artery disease in type 2 diabetes, focusing on current strategies for cardiovascular risk assessment and screening. While traditional risk factors such as hypertension, dyslipidemia, and hyperglycemia remain central to clinical evaluation, they often fail to fully capture the residual cardiovascular risk in diabetic patients. Advances in imaging, particularly coronary calcium scoring and computed tomography angiography, allow for the direct visualization of total plaque burden, providing a more refined assessment of risk. Functional tests and novel biomarkers, including high-sensitivity C-reactive protein and lipoprotein(a), further enhance the precision of risk stratification. Despite these advances, the clinical value of routine screening in asymptomatic diabetic individuals remains controversial. Evidence suggests that a selective, risk-based approach to screening may be more effective than universal testing, identifying high-risk patients who could benefit from more intensive preventive therapies. Emerging technologies, such as artificial intelligence and machine learning, promise to improve risk prediction by integrating clinical, imaging, and biomarker data into personalized care pathways. The review emphasizes the need to move from a reactive approach, based on symptom-driven evaluation, to a proactive strategy aimed at early identification of subclinical disease. By combining advanced imaging techniques, biomarker profiling, and updated risk algorithms, clinicians can better tailor preventive interventions, reduce adverse cardiovascular outcomes, and optimize long-term care. Further prospective studies are required to define the most effective and cost-efficient screening protocols for asymptomatic coronary artery disease in individuals with diabetes.
No takes yet. Share an insight, caveat, or question.
Santilli et al. (2025) conducted a review in Type 2 diabetes mellitus with asymptomatic coronary artery disease. Screening for asymptomatic coronary artery disease vs. Universal testing or symptom-driven evaluation was evaluated. A selective, risk-based approach to screening for asymptomatic coronary artery disease in patients with type 2 diabetes may be more effective than universal testing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: